Stock News | Market Tamer Stock and Options Training

A panel of advisers to the U.S. Centers for Disease Control and Prevention (CDC) on Friday will vote on the use of Pfizer's respiratory syncytial virus (RSV) vaccine in pregnant women, likely paving the way for it to become the country's first maternal shot for protecting babies from the virus. A working group of panel members who are set to present their analysis on the vaccine backed recommending the shots from September to January for women in the middle of their third trimester of pregnancy, according to documents published ahead of the meeting. The vaccine was approved by the U.S. Food and Drug Administration last month for use in women during the middle of the third trimester, at 32 to 36 weeks, to prevent lower respiratory tract infection and severe disease in infants until they are six months old.

Pharma Stock Roundup: EU Nod to PFE's Litfulo, FDA Priority Tag to MRK Applications

3 Bargain Stocks to Buy in a Market That's Priced for Perfection

2 Dividend Growth Stocks to Buy Right Now

13 Best Beaten Down Stocks To Buy Now

Is Pfizer Stock A Buy After The FDA Approved Its Updated Covid Shot?

With New COVID-19 Boosters in Tow, Which Is the Better Buy: Pfizer, BioNtech, or Moderna Stock?

AstraZeneca’s Rare-Disease Unit Buy Pfizer Portfolio for $1 Bln

Pfizer (PFE) Gains As Market Dips: What You Should Know

UPDATE 2-Moderna to cut mRNA drug substance production at Lonza facility

Moderna, Pfizer on the move on concerns about weak demand for COVID vaccines

Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference

Pfizer's (PFE) Alopecia Areata Drug Litfulo Receives EU Nod